Orthobiologic Digest™
Orthobiologic Digest™
September 21, 2026
Research. Evidence. Perspective.
Curated by Deborah Westergaard, MD
Welcome to this week's Orthobiologic Digest. Patients send me headlines every week about new regenerative treatments. Some are exciting. Some are very early. Some headlines outrun the evidence. My goal is to look critically at what was actually studied, in whom, and what we can honestly conclude.
1. Can One Injection Really Reverse Osteoarthritis?
Not in humans, not yet. But several teams in the federal NITRO program are getting remarkably interesting preclinical results.
The headline that caught my attention: “One injection reversed osteoarthritis in weeks” comes from researchers at the University of Colorado Boulder, CU Anschutz and Colorado State University. In animal models, the Colorado team reports that an experimental injectable therapy returned osteoarthritic joints toward a healthier state within four to eight weeks. The researchers are also developing a separate biomaterial approach designed to recruit the body's own progenitor cells to repair cartilage and bone defects.
There is also a separate UCLA NITRO team pursuing the same larger goal of regenerating osteoarthritic joints. UCLA researchers have specifically reported using mouse models to identify drug combinations capable of repairing articular cartilage and underlying bone. Their program is developing separate injectable approaches targeting cartilage and bone, with UCLA planning eventual human clinical trials.
That distinction matters. The dramatic “reversed osteoarthritis in weeks” result belongs to the Colorado animal work. UCLA has its own genuine mouse-model research within NITRO, but it is not the source of that particular headline.
Dr. Westergaard's Perspective
I am genuinely excited by both programs because they are looking beyond cartilage alone and treating the osteochondral unit, including the subchondral bone. That is where I think some of the most interesting work in joint preservation is occurring.
But the headline needs to stay attached to the experiment. The dramatic four-to-eight-week reversal being discussed in the media is preclinical animal work from the Colorado team, not evidence that one injection reverses osteoarthritis in people.
At the same time, UCLA's work is worth following separately. Their investigators are using mouse models to identify therapies aimed at regenerating cartilage and the bone beneath it, and their NITRO program is specifically designed to move those discoveries toward human trials.
We already have autologous approaches that allow us to treat appropriate subchondral pathology with concentrated bone marrow from the patient's own body. As these new pharmaceutical and biomaterial approaches move toward human testing, I would love to see them eventually compared not only with placebo or conventional care, but with our best autologous joint-preservation strategies.
The appropriate summary today is: remarkable science, real animal data, and human proof still to come.
Reader links
2. Spine Orthobiologics: Promising Signals, Messy Comparisons
A 2026 European Spine Journal review examined randomized trials of PRP and cell-based spine treatments. PRP showed encouraging mid-term signals for lumbar radiculopathy and lumbar facet pain, while intradiscal results were mixed. Trials differed substantially in patient selection, PRP preparation, dose, volume and technique. The positive trial associated with Gregory Lutz used provocative discography to identify concordant discogenic pain.
Dr. Westergaard's Perspective
I do not think we are always comparing like with like. I approach the spine as a functional unit. Ultrasound is excellent for many posterior soft-tissue targets, but it cannot see through bone. As targets become deeper and more anterior, that limitation matters; fluoroscopy remains essential for many spine procedures. Patients should ask how the pain generator was identified, what structures are being treated, what imaging will be used, and whether the physician's spine procedural training came from a short course or formal fellowship training with extensive hands-on experience.
Reader links
3. GLP-1s, Weight Loss and Musculoskeletal Health
A Runner's World piece asked what happens to muscle, bone and tendons as GLP-1-based medications drive substantial weight loss. Weight loss can reduce joint load, but rapid weight loss can also include lean-mass loss and inadequate protein or total energy. Observational tendon signals do not prove causation.
Dr. Westergaard's Perspective
These medications have helped many people, but weight loss is not always just fat loss. Both semaglutide and tirzepatide can be associated with lean-mass loss. Active patients should prioritize adequate protein, resistance training, sufficient nutrition and recovery. Most importantly, do not ignore sudden or unusual pain; early evaluation is better than discovering a tendon or other problem late.
Reader links
4. Dr. Annu Navani Brings Regenerative Spine Medicine to Forbes
Dr. Annu Navani has brought regenerative spine and joint medicine into a broader public conversation while contributing clinical research, including randomized work in discogenic low-back pain and newer early work involving Modic changes and subchondral vertebral treatment.
Dr. Westergaard's Perspective
I am genuinely thrilled to see Dr. Navani's work featured in Forbes. Her research has helped move this field forward and mainstream coverage helps patients learn that nonoperative options may exist. I especially want larger prospective studies that isolate what subchondral vertebral treatment adds in patients with Modic changes and how durable that benefit is.
Reader links
5. ACR vs AAPM&R: Two Views of PRP for Knee Osteoarthritis
ACR guidance is negative on PRP for knee and hip OA, while AAPM&R; considers PRP reasonable for selected mild-to-moderate knee OA after conservative care. The disagreement highlights a central problem: PRP is not one standardized treatment. Dose, leukocytes, processing, number of treatments, target and patient phenotype vary.
Dr. Westergaard's Perspective
My position is closer to AAPM&R. PRP has an important role in symptom management for many patients, including some with severe OA. For moderate-to-severe disease, native-joint preservation may require evaluation of the entire osteochondral unit, including subchondral bone. Orthobiologic treatment should begin with diagnosis, imaging and anatomy - not with a syringe.
Reader links
6. What Professional Athletes Are Being Offered: PRP, HA and A2M
A UCLA Health consumer piece featuring a sports-medicine physician discusses hyaluronic acid, PRP and alpha-2-macroglobulin. It is not a randomized comparison; it is a window into clinical practice. A2M is biologically interesting, but its clinical evidence base is smaller than PRP's.
Dr. Westergaard's Perspective
Anecdotal experience is not scientific proof, but clinical observations can generate useful questions. In my own practice, some of the most impressive knee OA results I have seen involve concentrated autologous bone marrow directed at appropriate subchondral pathology as part of treating the osteochondral unit. That is my clinical observation, not a randomized superiority claim. Clinical experience and clinical proof are both useful, but they answer different questions.
Reader links
7. Are Fascia and Myofascial Tissues Overlooked Pain Generators?
New 2026 research is strengthening the case that fascia and myofascial structures deserve more attention in chronic low-back pain. A retrospective study published in BMC Musculoskeletal Disorders in 2026 examined 58 patients treated with ultrasound-guided hydrodissection targeting trigger points in the longissimus lumborum muscle. Patients received either one PRP injection or two saline injections given a week apart.
Both groups experienced less pain at 12 weeks, with greater pain and disability improvements reported in the PRP group. However, the retrospective design, different injection schedules and short follow-up limit conclusions. This was a study of myofascial treatment, not proof of thoracolumbar fascia regeneration.
Dr. Westergaard's Perspective
I like this research because chronic back pain is not simply disc versus facet. Evaluating the functional spinal unit means considering the surrounding muscles and connective tissues as potential contributors and determining which structures actually explain the patient's symptoms.
The saline group improved too. That matters when asking how much benefit comes from hydrodissection and how much comes from PRP. The additional improvement reported with PRP is encouraging, but stronger comparative studies are needed before we can confidently separate those effects. My starting point remains the same: identify the pain generator before choosing the injection.
Reader link
Closing Perspective
The common thread this week is precision. A preclinical animal study is not a human cure. A guideline is not the same thing as the heterogeneous studies underneath it. A product name is not a diagnosis. Patient selection, imaging, anatomy, processing, dose, target and operator training all matter.
FAQ
Can an injection cure osteoarthritis?
Not at present. NITRO teams have reported cartilage and bone regeneration in osteoarthritic animal models, including dramatic Colorado animal-study results, but human trials have not yet established that a single injection reverses osteoarthritis in patients.
Is PRP recommended for knee arthritis?
Specialty guidance differs. AAPM&R; considers PRP reasonable for selected mild-to-moderate knee OA, while ACR guidance is more negative. PRP preparation, dose, patient selection and targets vary greatly.
Who should perform a spine orthobiologic procedure?
Ask specifically about spine procedural training: short-course exposure versus formal fellowship training with extensive hands-on interventional spine experience. Also ask how the pain generator was identified, what will be treated, and what imaging will be used.
Is ultrasound enough for every regenerative spine procedure?
No. Ultrasound is excellent for many superficial and posterior targets but cannot see through bone. Fluoroscopy remains important for many deeper targets and for contrast confirmation.
Can GLP-1 medications affect muscles or tendons?
Rapid weight loss can include lean-mass loss, and observational studies have raised tendon questions. Causation is not established. Adequate protein, resistance training, recovery and early evaluation of sudden pain are practical safeguards.
Does PRP work for severe knee osteoarthritis?
Some patients with advanced OA obtain meaningful symptom relief, but advanced disease may involve subchondral bone and other structures requiring a broader joint-preservation assessment.
What does functional-unit spine treatment mean?
It means evaluating the spine as an interconnected system rather than assuming every case is only a disc or facet problem. Treatment follows the identified pain generator.
Comments